- Home
- ALZN
ALZN
Alzamend Neuro Inc.
as 12-20-2024 4:00pm EST
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 7.0M | IPO Year: | 2021 |
| Target Price: | $32.00 | AVG Volume (30 days): | 174.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.06 - $15.06 | Next Earning Date: | 12-31-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alzamend Neuro Inc. News
ALZN Breaking Stock News: Dive into ALZN Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
TipRanks
10 days ago
Alzamend Neuro says net cash gained by financing activity $8.3M
Business Wire
11 days ago
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Business Wire
a month ago
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Benzinga
a month ago
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Business Wire
2 months ago
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Benzinga
2 months ago
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
MT Newswires
2 months ago
Alzamend Neuro Regains Nasdaq Compliance Over Listing Requirements
Compare ALZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALZN Alzamend Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.